Annual Drug Patent Expirations for PROMACTA
Promacta is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
